Gyre Therapeutics (NASDAQ: GYRE) director awarded 40,000 stock options at $5.95

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. director Renate Parry received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036. According to the disclosure, the award vests in 12 equal monthly installments through June 10, 2027, contingent on Parry’s continued service to the company. This is a compensation-related acquisition, with no open‑market buying or selling reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Parry Renate

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 40,000 options Exercise price: $5.95 per share Underlying shares: 40,000 shares +3 more

6 metrics

Option grant size 40,000 options Stock Option (Right to Buy) granted June 10, 2026

Exercise price $5.95 per share Exercise price of stock option grant

Underlying shares 40,000 shares Common stock underlying the options

Post-grant derivative holdings 40,000 options Total options following transaction for this award

Expiration date June 10, 2036 Option expiry for this grant

Vesting period end June 10, 2027 Final vesting date; 12 equal monthly installments

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for the reported transaction"

exercise price financial

"conversion_or_exercise_price of 5.9500 indicates the option exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"options "will vest in 12 equal monthly installments through June 10, 2027""

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-06-10" for the stock option grant"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 06:18 PM Accepted by SEC EDGAR 06/30/2026 - 06:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parry Renate

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.95	06/10/2026		A		40,000		(1)	06/10/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Thomas Eastling, as attorney-in-fact for Renate Parry	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did GYRE director Renate Parry report on this Form 4?

Renate Parry reported receiving a stock option grant for 40,000 shares of Gyre Therapeutics common stock. The award is a compensation-related acquisition, not an open-market trade, and gives the right to buy shares at a fixed exercise price.

What is the exercise price of Renate Parry’s GYRE stock options?

The stock options granted to Renate Parry have an exercise price of $5.95 per share. This is the price at which she can purchase Gyre Therapeutics common stock once the options vest and are exercisable, subject to the award’s terms.

How do Renate Parry’s GYRE stock options vest over time?

The 40,000 Gyre Therapeutics stock options vest in 12 equal monthly installments through June 10, 2027. Vesting is conditioned on Parry’s continued service to the company on each monthly vesting date during this period.

When do Renate Parry’s GYRE stock options expire?

The stock options granted to Renate Parry expire on June 10, 2036. After that expiration date, any unexercised options will lapse, and the right to purchase Gyre Therapeutics common stock under this grant will end.

Does this GYRE Form 4 show any open-market stock purchases or sales?

This Form 4 does not report any open-market purchases or sales of Gyre Therapeutics stock. It discloses only a compensation-related stock option grant to director Renate Parry, classified as a grant, award, or other acquisition.